Condition: Viral Infection · Hematopoietic Stem Cell Transplantation (HSCT) · Primary Immunodeficiency Disorders (PID) · Sponsor: Children's National Research Institute
This is a Phase I dose-escalation study to evaluate the safety of norovirus -specific T-cell (NST) therapy for chronic norovirus infection in participants following hematopoietic stem cell transplantation (HSCT) or who are immunocompromised due to PID and have not undergone HSCT, or Solid Organ Transplant (SOT) recipients.
This description comes directly from the study's public registry record.
Michael Keller, MD · 202-476-5843 · MKeller@childrensnational.org
Fahmida Hoq, MBBS, MS · 202-476-3634 · fhoq@childrensnational.org
Always discuss trial participation with your own doctor first.
| Children's National Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| National Institutes of Health (NIH) | Bethesda, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04691622